Jpmorgan Chase & CO Bio Atla, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Bio Atla, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,129 shares of BCAB stock, worth $1,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,129

Previous 8,340 86.46%

Holding current value

$1,569

Previous $11,000 90.91%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$1.17 - $2.05 $8,436 - $14,782	-7,211 Reduced 86.46%	1,129 $1,000
Q2 2024 Aug 12, 2024	SELL	$1.37 - $3.92 $30,445 - $87,114	-22,223 Reduced 72.71%	8,340 $11,000
Q1 2024 May 10, 2024	SELL	$1.88 - $3.46 $15,823 - $29,122	-8,417 Reduced 21.59%	30,563 $105,000
Q4 2023 Feb 12, 2024	SELL	$1.27 - $3.18 $8,329 - $20,857	-6,559 Reduced 14.4%	38,980 $95,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $294 - $531	173 Added 0.38%	45,539 $77,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $99,876 - $136,580	35,292 Added 350.33%	45,366 $136,000
Q1 2023 May 11, 2023	SELL	$2.3 - $8.25 $358,153 - $1.28 Million	-155,719 Reduced 93.92%	10,074 $26,000
Q4 2022 Feb 13, 2023	SELL	$6.29 - $11.01 $707,109 - $1.24 Million	-112,418 Reduced 40.41%	165,793 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $9,937 - $40,120	3,380 Added 1.23%	278,211 $2.14 Million
Q2 2022 Aug 11, 2022	BUY	$2.13 - $5.38 $550,811 - $1.39 Million	258,597 Added 1592.93%	274,831 $783,000
Q1 2022 May 11, 2022	BUY	$4.38 - $18.78 $5,461 - $23,418	1,247 Added 8.32%	16,234 $81,000
Q4 2021 Feb 10, 2022	SELL	$19.0 - $30.95 $218,671 - $356,203	-11,509 Reduced 43.44%	14,987 $295,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $780,042 - $1.16 Million	26,496 New	26,496 $780,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.3M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $50.5M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Bio Atla, Inc. Transaction History